Developer docs
API playgroundTry for free, no card

Search company profiles

CardioSignal

Full company profile

uuid000247t

Namestring
CardioSignal
Legal namestring
Precordior Ltd
Company typeenum
Private
Founded yearint
2017
Descriptiontext

CardioSignal (operating legal entity Precordior Ltd) is a Finland-based digital health company founded in 2017 as a University of Turku spin-off that develops a CE-marked Class IIb medical device mobile application for cardiac diagnostics. The product is built on proprietary gyrocardiography technology, which uses a smartphone's gyroscope and accelerometer to measure rotational heart motion during a one-minute measurement and applies a clinically validated algorithm to detect signs of atrial fibrillation, with 95.3% sensitivity and 96.0% specificity reported in clinical studies. The same method has demonstrated 89% diagnostic accuracy for heart failure detection in a multicenter study of over 1,000 participants published in JACC: Heart Failure. The IP base comprises 52 patents and 20+ peer-reviewed publications backed by 12+ years of academic research.

The company operates a hybrid revenue model. On the consumer side, the CardioSignal app is sold via subscription through Apple App Store and Google Play at €6.99/month, €17.99/quarter, or €44.99/year across 15 European countries, with 200,000+ users to date. On the B2B side, the company licenses its detection technology through "CardioSignal Inside," an SDK that lets partners embed CE-marked Afib detection into their own mobile applications (CardioSignal retains regulatory responsibility as legal manufacturer), and runs population health programs with insurance companies (LocalTapiola, DKV), healthcare providers (Mehiläinen, Heart Center Mølholm), and device manufacturers (OMRON Healthcare). Additional segments include pharma/CROs for clinical-trial digital endpoints and point-of-care clinical use.

CardioSignal has raised $23 million in total funding (€2.2M seed from Maki.vc in September 2021; $10M Series A led by DigiTx Partners in January 2024 with Sandwater and Maki.vc). The company is headquartered in Turku, Finland with a US subsidiary (CardioSignal Inc.) in Palo Alto, California, and is certified to ISO 13485 (medical device quality) and ISO 27001 (information security). The leadership team combines clinical cardiology (CEO Dr. Juuso Blomster, Medical Director Dr. Blaž Mrevlje), biosignal engineering (CTO Ilkka Korhonen), and corporate governance credibility (board members Ursula Burns and David J. Kim).

Short descriptiontext

CardioSignal is a Finland-based digital health company offering a CE-marked Class IIb medical device app that uses patented gyrocardiography technology to detect atrial fibrillation and heart failure via smartphone motion sensors, serving consumers, healthcare providers, insurers, and pharma/CROs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTurku, Finland
HQ citystring
Turku
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac diagnostics software, atrial fibrillation detection, digital cardiac biomarker, smartphone health monitoring, gyrocardiography technology
Industry4 codes
PRIMARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYCRACAQAC
ECG/EKG & Heart Rhythm Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Digital Cardiac Diagnostics Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Consumer App Subscriptions
TypeSubscription Recurring
Description

Direct-to-consumer subscription model through Apple App Store and Google Play. Subscribers pay monthly, quarterly, or annual fees to access the CardioSignal app for self-monitoring of atrial fibrillation. Auto-renewing subscriptions managed through app store billing systems.

cardiosignal.com
2SDK Licensing (CardioSignal Inside)
TypeLicensing Royalties
Description

B2B licensing model where partners integrate CardioSignal's CE-marked atrial fibrillation detection technology into their own mobile applications via SDK. Partners include healthcare providers, insurance companies, and app developers who embed medical-grade Afib detection without building their own regulated product.

cardiosignal.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details3 tiers
1Monthly subscription for individual self-monitoring
ModelSubscriptionBilling cadenceMonthly
Notes

6.99 EUR per month, auto-renews monthly

cardiosignal.com
2Quarterly subscription for individual self-monitoring
ModelSubscriptionBilling cadencePay-as-you-go
Notes

17.99 EUR per quarter, auto-renews every three months

cardiosignal.com
3Annual subscription for individual self-monitoring
ModelSubscriptionBilling cadenceAnnual
Notes

44.99 EUR per year, auto-renews annually

cardiosignal.com
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Core offering1 text field

CardioSignal develops a CE-marked Class IIb mobile medical device software that uses smartphone gyroscope and accelerometer sensors via patented gyrocardiography to measure heart motion and detect signs of atrial fibrillation in a one-minute measurement. The company sells directly to individual consumers through a subscription app and licenses its detection technology to enterprise partners (healthcare providers, insurers, pharma/CROs, and OEMs) through its CardioSignal Inside SDK for population screening, remote patient monitoring, and clinical trial endpoints.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 95-97% accuracy in detecting atrial fibrillation
+3 more records
Product overview1 text field

CardioSignal is a single unified mobile medical device product built on patented gyrocardiography technology that detects atrial fibrillation using a smartphone's built-in gyroscope and accelerometer. The core CardioSignal App is a CE-marked Class IIb medical device offered to consumers via subscription, with four deployment variants: Self-Monitoring (direct-to-consumer), Population Health Programs (for care providers and insurers), Point-of-Care Solutions (for clinical settings), and Pharma/CROs (for clinical trials). A complementary B2B offering called CardioSignal Inside is an SDK that enables partners to embed CardioSignal's CE-marked AFib detection into their own apps — as demonstrated in the OMRON connect app partnership. The product portfolio is completed by a Whitepaper resource on population health program implementation.

Product and service5 records
1CardioSignal App (Self-Monitoring)
CategoryConsumer Cardiac Self-Monitoring
Description

A CE-marked Class IIb medical device mobile application that uses smartphone motion sensors (gyroscope and accelerometer) to detect signs of atrial fibrillation in a 1-minute measurement, with clinically validated sensitivity of 95.3% and specificity of 96.0%. Targeted at individual consumers aged 18+ with risk factors (age, family history, hypertension, diabetes). Available via subscription (EUR 6.99/month, EUR 17.99/quarter, EUR 44.99/year) on iOS and Android in 15 European countries.

2CardioSignal Inside SDK
CategoryB2B Embedded Cardiac Detection SDK
Description

An SDK (software development kit) that allows B2B partners to embed CardioSignal's CE-marked atrial fibrillation detection and heart rate measurement into their own mobile applications as native features, without partners having to develop or certify their own regulated medical product. Regulatory responsibility remains with CardioSignal as legal manufacturer.

3Population Health Programs
CategoryPopulation Health Screening Program
Description

A digital atrial fibrillation detection program for care providers, hospitals, clinics, and insurance companies to implement targeted or population-wide atrial fibrillation screening and remote patient monitoring initiatives. Deployed via insurance-sponsored access (LocalTapiola, DKV) and healthcare-provider-sponsored access (Mehiläinen, Heart Center Mølholm) covering thousands of individuals per program.

4Point-of-Care Solutions
CategoryClinical Point-of-Care Cardiac Detection
Description

Clinical point-of-care atrial fibrillation detection offering for healthcare institutions, designed to reduce atrial fibrillation-related burden in clinical practice and enable primary-care physicians to screen for heart disease using a smartphone during patient visits.

5Pharma and CRO Cardiac Monitoring
CategoryClinical Trial Digital Endpoints
Description

CardioSignal's cardiac detection technology offered to pharmaceutical companies and Contract Research Organizations (CROs) for use as digital biomarkers and endpoints in clinical trials, drug development programs, and patient monitoring studies.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-28
Description

Leading private health insurer in Spain (part of ERGO Group) selected CardioSignal as winner of Desafio DKV 2025 innovation challenge. Partnership to integrate smartphone-based Afib detection into DKV's digital health ecosystem for insured customers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-05
Description

Finnish insurance company launched pilot program offering 5,000 customers aged 50-75 free access to CardioSignal for six months for atrial fibrillation screening. Partnership aims to prevent strokes through early detection.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-08
Description

Denmark's esteemed private hospital and cardiac ablation pioneer offering 12 months of complimentary CardioSignal access to patients post-ablation. Partnership enhances patient recovery monitoring and early arrhythmia relapse detection.

Strategic tierMinorTypeOthersAnnounced on2024-09-03
Description

CardioSignal presented clinical data at ESC 2024 annual meeting in London on atrial fibrillation detection reliability. CEO Dr. Juuso Blomster presented in Transforming Population Health session.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-18
Description

Nordic private healthcare provider continues population health program with 10,000 individuals for atrial fibrillation detection. Previously successfully engaged 8,500 individuals in 3 weeks with 93% user satisfaction.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-10-09
Description

CardioSignal joined AgeTech Collaborative portfolio after completing prestigious accelerator program, focused on improving accessibility of remote cardiac care for older adults.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-08
Description

CardioSignal atrial fibrillation detection became available in OMRON connect app Premium Service in selected European countries, integrating medical-grade Afib detection into OMRON's digital health ecosystem.

8JISEKI Health
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-10-11
Description

Collaboration to virtualize care paths for earlier detection of heart disease in the USA, focusing on vulnerable populations and health equity in cardiac remote patient monitoring.

cardiosignal.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Digital cardiac auscultation and ECG company combining AI software with clinician-grade stethoscopes and remote monitoring — closely comparable as a digital cardiac biomarker business spanning consumer, clinical, and pharma/CRO use cases.

TypeBroad incumbent
Description

Connected health device maker (BPM Core, ScanWatch with ECG/Afib detection) — comparable as a consumer-grade cardiac monitoring player with overlapping insurance partnership motion, though portfolio is broader than cardiac.

TypeDirect peer
Description

Belgian health tech company offering smartphone-based (PPG) atrial fibrillation detection via a CE-marked medical app and SDK — the closest direct peer to CardioSignal, competing head-to-head in European insurer-led population screening programs and SDK licensing.

TypeBroad incumbent
Description

Apple Watch ECG and Afib detection features represent the largest-scale consumer cardiac monitoring channel globally — comparable in clinical function but a broad incumbent; CardioSignal must differentiate on accuracy and clinical validation rather than hardware.

TypeBroad incumbent
Description

Broad incumbent in hospital and remote cardiac monitoring (BioTelemetry acquisition) — comparable as a cardiac RPM and population health player, though operating at much larger scale across multiple care settings.

TypeBroad incumbent
Description

Public US company behind the Zio long-term cardiac monitoring patch — comparable as a digital cardiac arrhythmia detection business serving clinicians and payers, though its modality (patch ECG) is clinical rather than consumer smartphone-based.

TypeDirect peer
Description

US-based company behind KardiaMobile, the leading consumer and clinical ECG-based Afib detection device/app — directly comparable to CardioSignal as a consumer-and-enterprise cardiac biomarker play, though AliveCor is hardware (single-lead ECG) rather than motion-sensor based.

TypeEmerging player
Description

Personal cardiac and vitals monitoring company (QardioArm, QardioCore ECG monitor) targeting consumer and remote patient monitoring — comparable in product breadth and D2C/clinical dual motion, though smaller and earlier-stage.

TypeBroad incumbent
Description

BodyGuardian remote cardiac monitoring platform acquired by Boston Scientific — comparable in remote cardiac monitoring and population-level arrhythmia detection, though focused on clinical-grade wearable patches rather than consumer smartphone apps.

TypeOthers
Description

Both a CardioSignal partner (CardioSignal embedded in OMRON connect app Premium) and a broader incumbent in consumer/clinical blood pressure monitors and ECG devices — relevant as a competitive force in the same distribution and end-customer set.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CardioSignal

Digital Cardiac Diagnostics Softwarecardiosignal.com

CardioSignal is a Finland-based digital health company offering a CE-marked Class IIb medical device app that uses patented gyrocardiography technology to detect atrial fibrillation and heart failure via smartphone motion sensors, serving consumers, healthcare providers, insurers, and pharma/CROs.

What CardioSignal does

CardioSignal (operating legal entity Precordior Ltd) is a Finland-based digital health company founded in 2017 as a University of Turku spin-off that develops a CE-marked Class IIb medical device mobile application for cardiac diagnostics. The product is built on proprietary gyrocardiography technology, which uses a smartphone's gyroscope and accelerometer to measure rotational heart motion during a one-minute measurement and applies a clinically validated algorithm to detect signs of atrial fibrillation, with 95.3% sensitivity and 96.0% specificity reported in clinical studies. The same method has demonstrated 89% diagnostic accuracy for heart failure detection in a multicenter study of over 1,000 participants published in JACC: Heart Failure. The IP base comprises 52 patents and 20+ peer-reviewed publications backed by 12+ years of academic research.

The company operates a hybrid revenue model. On the consumer side, the CardioSignal app is sold via subscription through Apple App Store and Google Play at €6.99/month, €17.99/quarter, or €44.99/year across 15 European countries, with 200,000+ users to date. On the B2B side, the company licenses its detection technology through "CardioSignal Inside," an SDK that lets partners embed CE-marked Afib detection into their own mobile applications (CardioSignal retains regulatory responsibility as legal manufacturer), and runs population health programs with insurance companies (LocalTapiola, DKV), healthcare providers (Mehiläinen, Heart Center Mølholm), and device manufacturers (OMRON Healthcare). Additional segments include pharma/CROs for clinical-trial digital endpoints and point-of-care clinical use.

CardioSignal has raised $23 million in total funding (€2.2M seed from Maki.vc in September 2021; $10M Series A led by DigiTx Partners in January 2024 with Sandwater and Maki.vc). The company is headquartered in Turku, Finland with a US subsidiary (CardioSignal Inc.) in Palo Alto, California, and is certified to ISO 13485 (medical device quality) and ISO 27001 (information security). The leadership team combines clinical cardiology (CEO Dr. Juuso Blomster, Medical Director Dr. Blaž Mrevlje), biosignal engineering (CTO Ilkka Korhonen), and corporate governance credibility (board members Ursula Burns and David J. Kim).

CardioSignal firmographics

Firmographics
Name
CardioSignal
Legal name
Precordior Ltd
Website
https://cardiosignal.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
CardioSignal is a Finland-based digital health company offering a CE-marked Class IIb medical device app that uses patented gyrocardiography technology to detect atrial fibrillation and heart failure via smartphone motion sensors, serving consumers, healthcare providers, insurers, and pharma/CROs.
Ownership category
akta.pro rank

CardioSignal industry classification

Industry
Product category
Digital Cardiac Diagnostics Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYCRACAQAC
ECG/EKG & Heart Rhythm Monitors (Consumer)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Cardiac diagnostics software
  • Atrial fibrillation detection
  • Digital cardiac biomarker
  • Smartphone health monitoring
  • Gyrocardiography technology

Where CardioSignal is headquartered

Location

Headquarters

HQ city
Turku
HQ country
Finland
HQ region
Europe

Offices2 records

Markets served

CardioSignal business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Consumer App Subscriptions: Direct-to-consumer subscription model through Apple App Store and Google Play. Subscribers pay monthly, quarterly, or annual fees to access the CardioSignal app for self-monitoring of atrial fibrillation. Auto-renewing subscriptions managed through app store billing systems.
  2. SDK Licensing (CardioSignal Inside): B2B licensing model where partners integrate CardioSignal's CE-marked atrial fibrillation detection technology into their own mobile applications via SDK. Partners include healthcare providers, insurance companies, and app developers who embed medical-grade Afib detection without building their own regulated product.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyMonthly subscription for individual self-monitoring
SubscriptionPay-as-you-goQuarterly subscription for individual self-monitoring
SubscriptionAnnualAnnual subscription for individual self-monitoring

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

CardioSignal product offering

Product offering

Core offering

CardioSignal develops a CE-marked Class IIb mobile medical device software that uses smartphone gyroscope and accelerometer sensors via patented gyrocardiography to measure heart motion and detect signs of atrial fibrillation in a one-minute measurement. The company sells directly to individual consumers through a subscription app and licenses its detection technology to enterprise partners (healthcare providers, insurers, pharma/CROs, and OEMs) through its CardioSignal Inside SDK for population screening, remote patient monitoring, and clinical trial endpoints.

Product overview

CardioSignal is a single unified mobile medical device product built on patented gyrocardiography technology that detects atrial fibrillation using a smartphone's built-in gyroscope and accelerometer. The core CardioSignal App is a CE-marked Class IIb medical device offered to consumers via subscription, with four deployment variants: Self-Monitoring (direct-to-consumer), Population Health Programs (for care providers and insurers), Point-of-Care Solutions (for clinical settings), and Pharma/CROs (for clinical trials). A complementary B2B offering called CardioSignal Inside is an SDK that enables partners to embed CardioSignal's CE-marked AFib detection into their own apps — as demonstrated in the OMRON connect app partnership. The product portfolio is completed by a Whitepaper resource on population health program implementation.

Differentiator

Problem solved

Functional benefit

Products and services

  • CardioSignal App (Self-Monitoring) A CE-marked Class IIb medical device mobile application that uses smartphone motion sensors (gyroscope and accelerometer) to detect signs of atrial fibrillation in a 1-minute measurement, with clinically validated sensitivity of 95.3% and specificity of 96.0%. Targeted at individual consumers aged 18+ with risk factors (age, family history, hypertension, diabetes). Available via subscription (EUR 6.99/month, EUR 17.99/quarter, EUR 44.99/year) on iOS and Android in 15 European countries.
  • CardioSignal Inside SDK An SDK (software development kit) that allows B2B partners to embed CardioSignal's CE-marked atrial fibrillation detection and heart rate measurement into their own mobile applications as native features, without partners having to develop or certify their own regulated medical product. Regulatory responsibility remains with CardioSignal as legal manufacturer.
  • Population Health Programs A digital atrial fibrillation detection program for care providers, hospitals, clinics, and insurance companies to implement targeted or population-wide atrial fibrillation screening and remote patient monitoring initiatives. Deployed via insurance-sponsored access (LocalTapiola, DKV) and healthcare-provider-sponsored access (Mehiläinen, Heart Center Mølholm) covering thousands of individuals per program.
  • Point-of-Care Solutions Clinical point-of-care atrial fibrillation detection offering for healthcare institutions, designed to reduce atrial fibrillation-related burden in clinical practice and enable primary-care physicians to screen for heart disease using a smartphone during patient visits.
  • Pharma and CRO Cardiac Monitoring CardioSignal's cardiac detection technology offered to pharmaceutical companies and Contract Research Organizations (CROs) for use as digital biomarkers and endpoints in clinical trials, drug development programs, and patient monitoring studies.

Quantifiable outcome

  • 95-97% accuracy in detecting atrial fibrillation
  • +3 more outcomes

Companies that use CardioSignal

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

CardioSignal technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

CardioSignal partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • DKVcoreStrategic or Co-development Partner · 28 November 2025Leading private health insurer in Spain (part of ERGO Group) selected CardioSignal as winner of Desafio DKV 2025 innovation challenge. Partnership to integrate smartphone-based Afib detection into DKV's digital health ecosystem for insured customers.
  • LocalTapiolacoreStrategic or Co-development Partner · 5 June 2025Finnish insurance company launched pilot program offering 5,000 customers aged 50-75 free access to CardioSignal for six months for atrial fibrillation screening. Partnership aims to prevent strokes through early detection.
  • Heart Center MolholmcoreStrategic or Co-development Partner · 8 October 2024Denmark's esteemed private hospital and cardiac ablation pioneer offering 12 months of complimentary CardioSignal access to patients post-ablation. Partnership enhances patient recovery monitoring and early arrhythmia relapse detection.
  • European Society of CardiologyminorOthers · 3 September 2024CardioSignal presented clinical data at ESC 2024 annual meeting in London on atrial fibrillation detection reliability. CEO Dr. Juuso Blomster presented in Transforming Population Health session.
  • MehilainencoreStrategic or Co-development Partner · 18 October 2023Nordic private healthcare provider continues population health program with 10,000 individuals for atrial fibrillation detection. Previously successfully engaged 8,500 individuals in 3 weeks with 93% user satisfaction.
  • AgeTech Collaborative from AARPminorStrategic or Co-development Partner · 9 October 2023CardioSignal joined AgeTech Collaborative portfolio after completing prestigious accelerator program, focused on improving accessibility of remote cardiac care for older adults.
  • OMRON HealthcarecoreStrategic or Co-development Partner · 8 November 2022CardioSignal atrial fibrillation detection became available in OMRON connect app Premium Service in selected European countries, integrating medical-grade Afib detection into OMRON's digital health ecosystem.
  • JISEKI HealthminorStrategic or Co-development Partner · 11 October 2022Collaboration to virtualize care paths for earlier detection of heart disease in the USA, focusing on vulnerable populations and health equity in cardiac remote patient monitoring.

Scale indicators7 records

Recent moves7 records

Expansion highlights8 records

CardioSignal competitors and assessment

Company assessment

Direct peers

  • Eko Health: Digital cardiac auscultation and ECG company combining AI software with clinician-grade stethoscopes and remote monitoring — closely comparable as a digital cardiac biomarker business spanning consumer, clinical, and pharma/CRO use cases.
  • FibriCheck: Belgian health tech company offering smartphone-based (PPG) atrial fibrillation detection via a CE-marked medical app and SDK — the closest direct peer to CardioSignal, competing head-to-head in European insurer-led population screening programs and SDK licensing.
  • AliveCor: US-based company behind KardiaMobile, the leading consumer and clinical ECG-based Afib detection device/app — directly comparable to CardioSignal as a consumer-and-enterprise cardiac biomarker play, though AliveCor is hardware (single-lead ECG) rather than motion-sensor based.

Broad incumbents

  • Withings: Connected health device maker (BPM Core, ScanWatch with ECG/Afib detection) — comparable as a consumer-grade cardiac monitoring player with overlapping insurance partnership motion, though portfolio is broader than cardiac.
  • Apple (Apple Watch ECG): Apple Watch ECG and Afib detection features represent the largest-scale consumer cardiac monitoring channel globally — comparable in clinical function but a broad incumbent; CardioSignal must differentiate on accuracy and clinical validation rather than hardware.
  • Philips (Cardiac Monitoring): Broad incumbent in hospital and remote cardiac monitoring (BioTelemetry acquisition) — comparable as a cardiac RPM and population health player, though operating at much larger scale across multiple care settings.
  • iRhythm Technologies: Public US company behind the Zio long-term cardiac monitoring patch — comparable as a digital cardiac arrhythmia detection business serving clinicians and payers, though its modality (patch ECG) is clinical rather than consumer smartphone-based.
  • Preventice Solutions (Boston Scientific): BodyGuardian remote cardiac monitoring platform acquired by Boston Scientific — comparable in remote cardiac monitoring and population-level arrhythmia detection, though focused on clinical-grade wearable patches rather than consumer smartphone apps.

Emerging players

  • Qardio: Personal cardiac and vitals monitoring company (QardioArm, QardioCore ECG monitor) targeting consumer and remote patient monitoring — comparable in product breadth and D2C/clinical dual motion, though smaller and earlier-stage.

Others

  • OMRON Healthcare: Both a CardioSignal partner (CardioSignal embedded in OMRON connect app Premium) and a broader incumbent in consumer/clinical blood pressure monitors and ECG devices — relevant as a competitive force in the same distribution and end-customer set.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

CardioSignal social profiles

Digital presence

CardioSignal compliance and trust

Trust signal

Compliance4 records

CardioSignal financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CardioSignal leadership team

Management profile

Number of profiles

Profiles7 records

CardioSignal subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CardioSignal funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CardioSignal M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CardioSignal

What does CardioSignal do?

CardioSignal develops a CE-marked Class IIb mobile medical device software that uses smartphone gyroscope and accelerometer sensors via patented gyrocardiography to measure heart motion and detect signs of atrial fibrillation in a one-minute measurement. The company sells directly to individual consumers through a subscription app and licenses its detection technology to enterprise partners (healthcare providers, insurers, pharma/CROs, and OEMs) through its CardioSignal Inside SDK for population screening, remote patient monitoring, and clinical trial endpoints.

Is CardioSignal a public or private company?

CardioSignal is a private company. It is classified as venture growth investor backed and is currently operating.

When was CardioSignal founded?

CardioSignal was founded in 2017. It employs 11 to 50 people.

Where is CardioSignal based?

CardioSignal is headquartered in Turku, Finland, in the Europe region.

How does CardioSignal make money?

Two revenue lines are on record. Consumer App Subscriptions are the primary driver. The others are SDK Licensing (CardioSignal Inside).

Who are CardioSignal's main competitors?

Direct peers on record are Eko Health, FibriCheck and AliveCor. Broad incumbents are Withings, Apple (Apple Watch ECG), Philips (Cardiac Monitoring), iRhythm Technologies and Preventice Solutions (Boston Scientific). Qardio is listed as an emerging player. OMRON Healthcare is listed as an others.

Does CardioSignal have an API?

No public API is recorded for CardioSignal.

What industry is CardioSignal in?

CardioSignal's product category is Digital Cardiac Diagnostics Software. Its primary akta.pro industry code is HLALAGAB, Cardiology Telemedicine Platforms, with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalNew technology uses a smartphone to analyze heart movement, detect heart failureResearchers at the University of Turku and CardioSignal developed a smartphone-based method to detect heart failure by analyzing chest vibrations. A study of 1,000 participants, including about 200 heart failure patients, found the method accurately identified most cases. The technique could enable remote monitoring and reduce healthcare costs.BenzingaIs Your Smartphone The Future Of Heart Disease Detection? This Finnish Startup Thinks SoCardioSignal, a Finnish startup, developed a system using smartphone motion sensors to detect heart disease, validated for clinical use. It can detect atrial fibrillation and is classified as a CE class IIa medical device. The company is working on adding detection for other heart conditions.Pulse 2.0CardioSignal: $10 Million Raised To Develop Solutions For Early Detection Of Heart DiseasesCardioSignal has closed a $10 million Series A funding round led by DigiTx Partners to support clinical validation and commercial expansion of its smartphone-based heart disease detection technology. The company, which utilizes motion data from smartphones to detect conditions like atrial fibrillation and heart failure, now has a total of $23 million raised since inception. This investment will facilitate the expansion of its medical device capabilities beyond its current availability in 15 countries.Tech.euCardioSignal secures $10M Series A for industry-first smartphone tech for heart disease detectionMedtech company CardioSignal closed a $10 million Series A funding round led by DigiTx Partners to support the clinical validation and commercial expansion of its smartphone-based heart disease detection technology. The funds will also enable the scaling of this software-as-medical-device, which utilizes smartphone motion data to detect conditions like atrial fibrillation and heart failure without specialized equipment. CardioSignal has now raised a total of $23 million since its inception.Business Wire BlogCardioSignal Raises $10 Million in Series A as the First Technology to Detect Major Heart Diseases without Specialized Medical HardwareCardioSignal closed $10 million in Series A funding led by DigiTx Partners, bringing total funding to $23 million. The company's smartphone-based gyrocardiography technology detects heart diseases like atrial fibrillation and heart failure without specialized equipment. The funding will support clinical validation and commercial expansion.Silicon CanalsCardioSignal Raises $10 Million in Series A as the First Technology to Detect Major Heart Diseases without Specialized Medical HardwareCardioSignal announced the closing of a $10 million Series A funding round led by DigiTx Partners, bringing its total raised capital to $23 million. The investment will support clinical validation and commercial expansion for its smartphone-based technology that detects major heart diseases using gyrocardiography without specialized medical hardware. This development aims to improve early detection of conditions like atrial fibrillation and heart failure in remote patients globally.BioSpaceCardioSignal Raises $10 Million in Series A as the First Technology to Detect Major Heart Diseases without Specialized Medical HardwareCardioSignal announced the closing of a $10 million Series A funding round led by DigiTx Partners, with participation from Sandwater and Maki.vc. The company develops digital health software that uses smartphone sensors to detect major heart diseases such as atrial fibrillation and heart failure without specialized medical hardware. This investment will fund further clinical validation and commercial expansion of its technology, which is already available in 15 countries.ArcticstartupFinnish CardioSignal raises $10M in Series A funding for smartphone-based heart disease detectionFinnish health tech company CardioSignal secured $10 million in Series A funding led by DigiTx Partners, bringing its total capital raised to $23 million. The funds will support the clinical validation of its smartphone-based heart disease detection technology and expand commercial efforts for conditions such as atrial fibrillation and heart failure.Omron-HealthcareOMRON Healthcare announces partnership with CardioSignal, establishing a cross-company cooperation to innovate early Cardiovascular Disease Detection and Remote Patient Monitoring at scale.OMRON Healthcare announced a partnership with CardioSignal on November 8, 2022, to collaborate on early cardiovascular disease detection and remote patient monitoring solutions. As the first result of this collaboration, CardioSignal's atrial fibrillation detection technology, which offers 96% detection accuracy, will be integrated into the OMRON connect Premium Service app in selected European countries including Austria, Finland, France, Germany, Ireland, Italy, Spain, Sweden, Switzerland, and the United Kingdom. The partnership aims to address the growing burden of cardiovascular disease, as over one billion adults worldwide are hypertensive and those with atrial fibrillation face nearly five times greater risk of stroke.TalouselamaSuomalaisyhtiön sovellus tunnistaa vaarallisen ja yleisen sydäntaudin kännykän kautta, yhtiö sai miljoonarahoituksen – ”Vaarallinen hoitamattomana vaikka olisi oireetonkin”CardioSignal, a Finnish app, received 2.2 million euros in seed funding from domestic and international investors. The app detects heart conditions by measuring resting heart rate via a smartphone placed on the chest. The company's CEO said the app is dangerous even if asymptomatic.